Survodutide and Mazdutide: The Next Wave of Multi-Agonists

Retatrutide made triple agonism famous, but the pipeline behind it is wider: survodutide and mazdutide represent a different design bet — dual agonists that pair GLP-1 with glucagon, skipping GIP entirely.

The glucagon question

Glucagon-receptor agonism is associated in models with energy-expenditure and hepatic effects — output-side biology, versus the intake-side signalling of GLP-1. Duals built on this pairing ask whether GIP was ever the necessary ingredient.

The two compounds

Survodutide (Boehringer/Zealand) and mazdutide (Lilly/Innovent) are both in late-stage clinical programs with steadily publishing datasets — meaning fresh comparison literature for researchers working the receptor-contribution question that our GLP-1 comparison guide frames.

Research positioning

With retatrutide (triple), tirzepatide (GLP-1+GIP) and these glucagon-forward duals, in-vitro researchers can now decompose multi-agonism combinatorially — which receptor pairs produce which signalling signatures. It is arguably the most interesting design-of-experiments moment metabolic research has had. Both compounds are on our expansion watchlist.

Trade note: our wholesale program supplies Australian-sourced peptides to research businesses Australia-wide, with white-label options for those building their own range.

All compounds discussed are for in-vitro laboratory research only and are not for human or veterinary use.